Generex Biotechnology Corporation (GNBT)

Recent filings

Generex Announces Terry Thompson as Chief Operating Officer - June 25, 2018

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income ... - June 11, 2018

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income... - March 16, 2018

Generex Biotechnology: Thank You, Dr. Anderson. I Would Like To Now Introduce Dr. Hal Haines With Nugenerex Diagnostics, Formerly Hds Hema Diagnostics. Dr. Haines, Please - Jan. 8, 2018

Generex CEO Provides 2017 Year-End Summary to Stakeholders - Jan. 4, 2018

Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018 - Jan. 3, 2018

Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy - Jan. 3, 2018

Generex Biotechnology: Of $700,000 Usd License Fee From - Jan. 2, 2018

Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals - Jan. 2, 2018

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans - Dec. 18, 2017

Termination of a Material Definitive - Dec. 18, 2017

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income... - Dec. 14, 2017

Generex Biotechnology: Generex Announces Collaboration With - Dec. 12, 2017

Generex Biotechnology: In Combination With Ae37 In Patients With Triple-Negative Breast Cancer - Dec. 11, 2017

Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China - Dec. 7, 2017

Amendments to Articles of Incorporation or - Dec. 4, 2017

Generex Announces Upgrade to OTCQB® Venture Market - Nov. 30, 2017

Tier Change - Nov. 30, 2017

Generex Biotechnology: Generex Announces Results Of Annual Stockholders’ Meeting - Nov. 27, 2017

Generex Biotechnology: Form, Schedule Or Registration Statement No Filing Party: Date Filed: EXPLANATORY NOTE - Nov. 6, 2017

Generex Biotechnology Corporation Just Filed Its Annual Report: Note 10 - Net (Loss)... - Oct. 26, 2017

Generex Biotechnology Corporation releases salary data. CEO sees compensation fall -64% - Oct. 13, 2017

Entry into a Material Definitive - Aug. 29, 2017

Preliminary Proxy Soliciting materials - Aug. 8, 2017

Generex Biotechnology: In Combination With Ae37 In Patients With Triple-Negative Breast Cancer - Aug. 1, 2017

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 9 - Net (Loss)... - June 15, 2017

Departure of Directors or Certain - May 26, 2017

Termination of a Material Definitive - May 22, 2017

Entry into a Material Definitive - April 27, 2017

Other preliminary proxy statements - April 18, 2017

Symbol Change - April 10, 2017

Financial Statements and - March 31, 2017

Generex Biotechnology: Generex Announces $115M Convertible Preferred Stock Financing; First Tranche Satisfies Emmaus Deposit - March 29, 2017

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 7 - Net (Loss)... - March 22, 2017

Generex Biotechnology: Generex Announces Reverse Stock Split - March 17, 2017

Notification of inability to timely file Form 10-Q or 10-QSB - March 17, 2017

Deleted Symbol - March 14, 2017

Entry into a Material Definitive - March 6, 2017

Entry into a Material Definitive - Feb. 24, 2017

Statement of acquisition of beneficial ownership by individuals - Feb. 16, 2017

Generex Biotechnology: Generex Announces Elimination Of Outstanding Derivative Securities - Feb. 15, 2017

Financial Statements and - Jan. 25, 2017

Entry into a Material Definitive - Jan. 20, 2017

Entry into a Material Definitive - Jan. 20, 2017

Generex Biotechnology: Securities And Exchange Commission - Jan. 20, 2017

Tier Change - Jan. 19, 2017

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 6 – Net (Loss)... - Jan. 18, 2017

Generex Biotechnology Corporation Just Filed Its Annual Report: Net Loss per Common... - Jan. 17, 2017

Tier Change - Jan. 14, 2017

Generex Biotechnology: Securities And Exchange Commission - Jan. 13, 2017

Tier Change - July 23, 2016

Generex Biotechnology Corporation's President & CEO just picked up 14,890,033 shares - Feb. 12, 2016

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 6 – Net (Loss)... - Jan. 14, 2016

OTCQB Certification - Dec. 1, 2015

Generex Announces Memorandum of Understanding in respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine - Oct. 15, 2015

Generex Announces Memorandum of Understanding in respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine - Oct. 15, 2015

Generex Announces Agreement to Acquire Equity Interest in MediTemp Ltd. - Oct. 13, 2015

Generex Announces Agreement to Acquire Equity Interest in MediTemp Ltd. - Oct. 13, 2015

Generex Biotechnology Corporation Just Filed Its Annual Report: Net Loss per Common... - Oct. 9, 2015

Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd. - Oct. 6, 2015

Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd. - Oct. 6, 2015

Generex Announces Issuance of Buccal Cannabis White Paper - Oct. 1, 2015

Generex Announces Issuance of Buccal Cannabis White Paper - Oct. 1, 2015

Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems - Sept. 30, 2015

Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems - Sept. 30, 2015

Generex Announces Commencement of Buccal Leuprolide R&D Work - Sept. 8, 2015

Generex Announces Commencement of Buccal Leuprolide R&D Work - Sept. 8, 2015

Generex Announces Formalization of Buccal Cannabis Co-Development Plan - Sept. 2, 2015

Generex Announces Formalization of Buccal Cannabis Co-Development Plan - Sept. 2, 2015

Generex Announces Issuance of Buccal Insulin White Paper - Aug. 27, 2015

Generex Announces Issuance of Buccal Insulin White Paper - Aug. 27, 2015

Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project - Aug. 25, 2015

Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project - Aug. 25, 2015

Generex Biotechnology: Securities And Exchange Commission - Aug. 20, 2015

Generex Biotechnology Corporation just filed a prospectus, suggesting it plans to soon issue some securities - Aug. 4, 2015

Generex Biotechnology Corporation Just Received a Notice of Effectiveness - July 31, 2015

General form for registration of securities under the Securities Act of 1933 - July 17, 2015

General form for registration of securities under the Securities Act of 1933 - July 17, 2015

Revised definitive proxy soliciting materials - July 14, 2015

Other definitive proxy statements - July 7, 2015

Preliminary Proxy Soliciting materials - June 25, 2015

Generex Biotechnology: Generex Announces Capital Investment - June 25, 2015

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 6 – Net Income... - June 5, 2015

Other preliminary proxy statements - June 2, 2015

Generex Biotechnology Corporation director just picked up 5,874,162 shares - April 27, 2015

Generex Biotechnology: Item 5.02. Departure Of Directors And Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers - April 7, 2015

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 7 – Net Income... - March 6, 2015

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 7 – Net Income... - Dec. 12, 2014

Annual report [Section 13 and 15(d), not S-K Item 405] - Oct. 17, 2014

Generex Biotechnology Corporation director just picked up 35,714 shares - Oct. 8, 2014

Generex Biotechnology Corporation director just picked up 35,714 shares - Oct. 8, 2014

Generex Biotechnology Corporation's President & CEO just picked up 470,726 shares - Oct. 8, 2014

Securities to be offered to employees in employee benefit plans - July 3, 2014

Quarterly report [Sections 13 or 15(d)] - June 6, 2014

Generex Biotechnology: Submission Of Matters To A Vote Of Security Holders - May 23, 2014

[Paper] - May 6, 2014

Revised definitive proxy soliciting materials - May 5, 2014

Generex Biotechnology Corporation just filed a prospectus, suggesting it plans to soon issue some securities - April 17, 2014

Generex Biotechnology Corporation Just Received a Notice of Effectiveness - April 16, 2014

Other definitive proxy statements - April 1, 2014

Sorry, no schedule available for this company

No known shareholders

Generex Biotechnology Corporation (GNBT)

140

cctranscripts

today

Generex Announces Terry Thompson as Chief Operating Officer http://www.otcmarkets.com/stock/GNBT/news?id=196371

cctranscripts

June 11, 2018

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income ... http://www.conferencecalltranscripts.org/pink/summary?id=5013140

cctranscripts

March 16, 2018

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income... http://www.conferencecalltranscripts.org/pink/summary?id=4714585

cctranscripts

Jan. 8, 2018

Generex Biotechnology: Thank You, Dr. Anderson. I Would Like To Now Introduce Dr. Hal Haines With Nugenerex Diagnostics, Formerly Hds Hema Diagnostics. Dr. Haines, Please http://www.conferencecalltranscripts.org/pink/summary?id=4475945

cctranscripts

Jan. 4, 2018

Generex CEO Provides 2017 Year-End Summary to Stakeholders http://www.otcmarkets.com/stock/GNBT/news?id=179563

cctranscripts

Jan. 3, 2018

Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy http://www.otcmarkets.com/stock/GNBT/news?id=179378

cctranscripts

Jan. 3, 2018

Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018 http://www.otcmarkets.com/stock/GNBT/news?id=179390

cctranscripts

Jan. 2, 2018

Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals http://www.otcmarkets.com/stock/GNBT/news?id=179307

cctranscripts

Jan. 2, 2018

Generex Biotechnology: Of $700,000 Usd License Fee From http://www.conferencecalltranscripts.org/pink/summary?id=4457884

cctranscripts

Dec. 18, 2017

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans http://www.otcmarkets.com/stock/GNBT/news?id=178391

cctranscripts

Dec. 18, 2017

Termination of a Material Definitive http://www.conferencecalltranscripts.org/pink/summary?id=4425798

cctranscripts

Dec. 14, 2017

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 5 - Net Income... http://www.conferencecalltranscripts.org/pink/summary?id=4417909

cctranscripts

Dec. 12, 2017

Generex Biotechnology: Generex Announces Collaboration With http://www.conferencecalltranscripts.org/pink/summary?id=4410147

cctranscripts

Dec. 11, 2017

Generex Biotechnology: In Combination With Ae37 In Patients With Triple-Negative Breast Cancer http://www.conferencecalltranscripts.org/pink/summary?id=4406322

cctranscripts

Dec. 7, 2017

Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China http://www.otcmarkets.com/stock/GNBT/news?id=177536

cctranscripts

Dec. 4, 2017

Amendments to Articles of Incorporation or http://www.conferencecalltranscripts.org/pink/summary?id=4386847

cctranscripts

Nov. 30, 2017

Generex Announces Upgrade to OTCQB® Venture Market http://www.otcmarkets.com/stock/GNBT/news?id=176780

cctranscripts

Nov. 30, 2017

Tier Change http://www.otcmarkets.com/market-activity/corpActions.jsp?index=11&symbol=GNBT&actionDate=1512018000000

cctranscripts

Nov. 27, 2017

Generex Biotechnology: Generex Announces Results Of Annual Stockholders’ Meeting http://www.conferencecalltranscripts.org/pink/summary?id=4361774

cctranscripts

Nov. 6, 2017

Generex Biotechnology: Form, Schedule Or Registration Statement No Filing Party: Date Filed: EXPLANATORY NOTE http://www.conferencecalltranscripts.org/pink/summary?id=4291852
 


Feedback